URGENT: Levemir® discontinuation

Posted on:

URGENT: Levemir® discontinuation –further support for practices and position statement for non-responders ahead of the 30 November deadline

With the national deadline of 30 November 2026 fast approaching, the number of patients still prescribed Levemir® has reduced significantly. Four additional capacity support offers are now live and able to accept referrals from GP practices.

To support practices, we have produced:

  • a three-page summary of the additional Levemir® switching support offers available across NEL and
  • a position statement on the approach to patients who do not respond to requests to switch from Levemir®

These offers provide additional clinical capacity for eligible patients and do not replace switching by GP practices or existing specialist diabetes pathways.

Practices should continue to review and switch patients where they have the appropriate clinical expertise, using existing specialist diabetes pathways where needed.

Further information can be found in our updated guidance note: URGENT: Levemir® discontinuation – additional support for practices ahead of the 30th November dead… Thank you for your continued work to safely transition patients. For clinical queries or to escalate concerns about specific patients who are still prescribed Levemir®, please contact nelondonicb.prescribingqueries@nhs.net

This website is for healthcare professions only.

It is not for public use.